Cargando…
Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis
OBJECTIVE: We performed a meta-analysis of randomized double-blinded placebo controlled trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major depressive disorder (MDD) including treatment resistant depression (TRD) and major depression with suicide ideation (...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077059/ https://www.ncbi.nlm.nih.gov/pubmed/33888663 http://dx.doi.org/10.9758/cpn.2021.19.2.341 |
_version_ | 1783684808316026880 |
---|---|
author | Wang, Sheng-Min Kim, Nak-Young Na, Hae-Ran Lim, Hyun Kook Woo, Young Sup Pae, Chi-Un Bahk, Won-Myong |
author_facet | Wang, Sheng-Min Kim, Nak-Young Na, Hae-Ran Lim, Hyun Kook Woo, Young Sup Pae, Chi-Un Bahk, Won-Myong |
author_sort | Wang, Sheng-Min |
collection | PubMed |
description | OBJECTIVE: We performed a meta-analysis of randomized double-blinded placebo controlled trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major depressive disorder (MDD) including treatment resistant depression (TRD) and major depression with suicide ideation (MDSI). METHODS: Mean change in total scores on Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to different time-points were our primary outcome measure. Secondary efficacy measures included rate of remission of depression and resolution of suicidality. RESULTS: Eight DB-RCTs (seven published and one un-published) covering 1,488 patients with MDD were included. Esketamine more significantly improved MADRS total scores than placebo starting from 2−4 hours after the first administration (standardized mean difference, −0.41 [95% CI, −0.58 to −0.25], p < 0.00001), and this superiority maintained until end of double-blinded period (28 days). Sub-group analysis showed that superior antidepressant effects of esketamine over placebo in TRD and MDSI was observed from 2−4 hours, which was maintained until 28 days. Resolution of suicide in MDSI was also greater for esketamine than for placebo at 2−4 hours (OR of 2.04, 95% CIs, 1.37 to 3.05, p = 0.0005), but two groups did not statistically differ at 24 hours and day 28. Total adverse events (AEs), and other common AEs including dissociation, blood pressure increment, nausea, vertigo, dysgeusia, dizziness, and somnolence were more frequent in esketamine than in placebo group. CONCLUSION: Esketamine showed rapid antidepressant effects in patients with MDD, including TRD and MDSI. The study also suggested that esketamine might be associated with rapid anti-suicidal effects for patients with MDSI. |
format | Online Article Text |
id | pubmed-8077059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Korean College of Neuropsychopharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-80770592021-05-31 Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis Wang, Sheng-Min Kim, Nak-Young Na, Hae-Ran Lim, Hyun Kook Woo, Young Sup Pae, Chi-Un Bahk, Won-Myong Clin Psychopharmacol Neurosci Original Article OBJECTIVE: We performed a meta-analysis of randomized double-blinded placebo controlled trials (DB-RCTs) to investigate efficacy and safety of intranasal esketamine in treating major depressive disorder (MDD) including treatment resistant depression (TRD) and major depression with suicide ideation (MDSI). METHODS: Mean change in total scores on Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to different time-points were our primary outcome measure. Secondary efficacy measures included rate of remission of depression and resolution of suicidality. RESULTS: Eight DB-RCTs (seven published and one un-published) covering 1,488 patients with MDD were included. Esketamine more significantly improved MADRS total scores than placebo starting from 2−4 hours after the first administration (standardized mean difference, −0.41 [95% CI, −0.58 to −0.25], p < 0.00001), and this superiority maintained until end of double-blinded period (28 days). Sub-group analysis showed that superior antidepressant effects of esketamine over placebo in TRD and MDSI was observed from 2−4 hours, which was maintained until 28 days. Resolution of suicide in MDSI was also greater for esketamine than for placebo at 2−4 hours (OR of 2.04, 95% CIs, 1.37 to 3.05, p = 0.0005), but two groups did not statistically differ at 24 hours and day 28. Total adverse events (AEs), and other common AEs including dissociation, blood pressure increment, nausea, vertigo, dysgeusia, dizziness, and somnolence were more frequent in esketamine than in placebo group. CONCLUSION: Esketamine showed rapid antidepressant effects in patients with MDD, including TRD and MDSI. The study also suggested that esketamine might be associated with rapid anti-suicidal effects for patients with MDSI. Korean College of Neuropsychopharmacology 2021-05-31 2021-05-31 /pmc/articles/PMC8077059/ /pubmed/33888663 http://dx.doi.org/10.9758/cpn.2021.19.2.341 Text en Copyright© 2021, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Wang, Sheng-Min Kim, Nak-Young Na, Hae-Ran Lim, Hyun Kook Woo, Young Sup Pae, Chi-Un Bahk, Won-Myong Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis |
title | Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis |
title_full | Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis |
title_fullStr | Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis |
title_full_unstemmed | Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis |
title_short | Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis |
title_sort | rapid onset of intranasal esketamine in patients with treatment resistant depression and major depression with suicide ideation: a meta-analysis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077059/ https://www.ncbi.nlm.nih.gov/pubmed/33888663 http://dx.doi.org/10.9758/cpn.2021.19.2.341 |
work_keys_str_mv | AT wangshengmin rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis AT kimnakyoung rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis AT nahaeran rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis AT limhyunkook rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis AT wooyoungsup rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis AT paechiun rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis AT bahkwonmyong rapidonsetofintranasalesketamineinpatientswithtreatmentresistantdepressionandmajordepressionwithsuicideideationametaanalysis |